Claims

1. The use of a compound that is seladelpar or a salt thereof in the manufacture of an oral medicament for treating primary biliary cholangitis at a dose of 5 mg/day or 10 mg/day, when the dose is calculated as seladelpar.

2. The use of claim 1 where the compound is seladelpar L-lysine dihydrate.

3. The use of claim 1 or 2 where the dose of the compound is 5 mg/day.

4. The use of claim 1 or 2 where the dose of the compound is 10 mg/day.

5. The use of any one of claims 1 to 4 where the compound is administered once/day.